(Q38649661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Current Controversies With Recent Cholesterol Treatment Guidelines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Elizabeth Phillips

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

25 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacy Practice

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

15-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

US pharmacists' effect as team members on patient care: systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Statin therapy for primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Appropriateness of statins in patients aged ≥80 years and comparison to other age groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Statins for the primary prevention of cardiovascular disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

NLA Task Force on Statin Safety--2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio (GISSI)-Prevenzione Trial on fish oil and vitamin E supplementation in myocardial infarction survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

An assessment by the Statin Cognitive Safety Task Force: 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Statins and cognitive function: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

An assessment by the Statin Diabetes Safety Task Force: 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

An assessment by the Statin Muscle Safety Task Force: 2014 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effect of statins on skeletal muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Effect of statins on creatine kinase levels before and after a marathon run.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The relationship of vitamin D deficiency to statin myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

A systematic review of statin-induced muscle problems in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015615880

21 January 2018

Identifiers

DOI

10.1177/0897190015615880

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26611871%20AND%20SRC:MED&resulttype=core&format=json